Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 11/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907827 | 0.91 | SLC9A1 (0.42) | HTR5ASLC9A1 | |
| SCHEMBL9907823 | 0.89 | HTR5A (0.54) | HTR5ASLC9A1 | |
| SCHEMBL15500584 | 0.89 | PTGDR2 (0.35) | HTR5ACDC7CCNE1CDK2DBF4 | |
| SCHEMBL9909233 | 0.88 | CDC7 (0.39) | HTR5ACDC7CCNE1CDK2DBF4 | |
| SCHEMBL9907850 | 0.87 | HTR5A (0.44) | HTR5ASLC9A1 | |
| SCHEMBL9907859 | 0.86 | HTR2B (0.42) | HTR5ASLC9A1 | |
| SCHEMBL9907495 | 0.84 | PTGDR2 (0.41) | CDC7CCNE1CDK2DBF4LIMK1 | |
| SCHEMBL9907828 | 0.84 | HTR5A (0.44) | HTR5ASLC9A1 | |
| SCHEMBL9907837 | 0.83 | HTR5A (0.47) | HTR5ASLC9A1PTGDR2 | |
| SCHEMBL9907846 | 0.83 | HTR5A (0.47) | HTR5ASLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885CDC7 4154/4885CCNE1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.